Inhibrx Future Growth

Future criteria checks 2/6

Inhibrx is forecast to grow earnings and revenue by 9.1% and 59.7% per annum respectively while EPS is expected to grow by 13.1% per annum.

Key information

9.1%

Earnings growth rate

13.1%

EPS growth rate

Biotechs earnings growth28.5%
Revenue growth rate59.7%
Future return on equityn/a
Analyst coverage

Low

Last updated13 May 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqGM:INBX.V - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026122-296N/AN/A1
12/31/20252-361N/AN/A1
12/31/2024N/A-316N/AN/A2
3/31/20242-271-222-216N/A
12/31/20232-241-198-193N/A
9/30/20230-189-169-167N/A
6/30/20231-172-144-144N/A
3/31/20231-163-129-128N/A
12/31/20222-145-116-115N/A
9/30/20225-125-108-107N/A
6/30/20227-111-91-90N/A
3/31/20227-94-87-86N/A
12/31/20217-82-81-80N/A
9/30/20217-78-74-73N/A
6/30/202111-78-75-73N/A
3/31/202113-75-64-62N/A
12/31/202013-76-49-48N/A
9/30/202010-75-46-45N/A
6/30/20206-74-33-31N/A
3/31/20206-68-36-34N/A
12/31/201913-51-34-32N/A
9/30/201915-40-29-27N/A
6/30/201915-30-29-27N/A
3/31/201914-26-28-27N/A
12/31/20189-31-25-23N/A
9/30/20187-35-24-23N/A
12/31/20178-19N/A-19N/A
12/31/20167-8N/A-18N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: INBX.V is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: INBX.V is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: INBX.V is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: INBX.V's revenue (59.7% per year) is forecast to grow faster than the US market (8.5% per year).

High Growth Revenue: INBX.V's revenue (59.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if INBX.V's Return on Equity is forecast to be high in 3 years time


Discover growth companies